A New Vision for the Eye: Unmet Ocular Drug Delivery Needs

Pharmaceutical Research

Volumn 32, Issue 9, 2015, Pages 2814-2823

  Rivers, Hongwen M ^a   Ray Chaudhuri, Siladitya ^a   Shah, Jaymin C ^b   Mittal, Sachin ^c  

^a ALLERGAN INC   (United States)

^b PFIZER INC   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; DRUG;

AGE RELATED MACULAR DEGENERATION; ARTICLE; BIODEGRADABLE IMPLANT; BLINDNESS; CATARACT; CORNEA PERMEABILITY; CYTOMEGALOVIRUS INFECTION; DIABETIC RETINOPATHY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; GLAUCOMA; INTRAOCULAR DRUG ADMINISTRATION; LIFESPAN; OPHTHALMIC DRUG DELIVERY DEVICE; OPTICAL COHERENCE TOMOGRAPHY; PERMEABILITY; PREVALENCE; PRIORITY JOURNAL; PROTEIN STABILITY; SUSTAINED DRUG RELEASE; TREATMENT DURATION; VISUAL IMPAIRMENT; WORK EXPERIENCE; ANIMAL; DRUG EFFECTS; EYE; EYE DISEASES; HUMAN; PROCEDURES;

ADMINISTRATION, OPHTHALMIC; ANIMALS; DRUG DELIVERY SYSTEMS; EYE; EYE DISEASES; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84938750325     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1717-z     Document Type: Article

References (21)

1. World Population Ageing 1950-2050, Population Division, DESA, United Nations.
2. Kompella UB, Kadam RS, Lee VH. Recent advances in ophthalmic drug delivery. Ther Deliv. 2010;1(3):435-56.
3. Amo EMD, Urtti A. Current and future ophthalmic drug delivery systems: a shift to the posterior segment. Drug Discov Today. 2008;13(3/4):135-43.
4. Zhang K, Zhang L, Weinreb RN. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov. 2012;11:541-59.
5. Zhang K, Hopkins JJ, Heier JS, Birch DG, Halperin LS, Albini TA, et al. Ciliary neurotrophic factor delivered by encapsulated intraocular implants for treatment of geographic atrophy in age-related macular degeneration. PNAS. 2011;108(15):6241-5.
6. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6(4):389-95.
7. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodeling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEFG. Development. 1998;125(9):1591-8.
8. Mariotti SP. Global data on visual impairments 2010, World Health Organization, 2012.
9. Friedlaender MH, Protzko E. Clinical development of 1% azithromycin in DuraSite®, a topical azalide anti-infective for ocular surface therapy. Clin Opthalmol. 2007;1(1):3-10.
10. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva. A literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87(12):1479-88.
11. Abdelkader H, Alany RG. Controlled and continuous release ocular drug delivery systems: Pros and Cons. Curr Drug Deliv. 2012;9:421-30.
12. Weiner A. Drug delivery system in ophthalmic applications. In: Yorio T, Clark AF, Wax MB, editors. Ocular therapeutics, eye of new discoveries. NY: Academic; 2008. p. 7-43.
13. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12(3):348-60.
14. Durairaj C, Shah J, Senapati S, Kompella U. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res. 2008;26(5):1236-60.
15. Edelhauser HE, Rowe-Rendleman CL, Robinson MR, Dawson DG, Chader GJ, Grossniklaus HM, et al. Ophthalmic drug delivery systems for the retinal diseases, basic research to clinical applications. Invest Ophthalmol Vis Sci. 2010;51(11):5430-18.
16. Olsen TW, Aaberg SY, Geroski DH, Edelhauser HF. Human sclera: thickness and surface area. Am J Oph. 1998;125(2):237-41.
17. Maurice DM, Polgar J. Diffusion across the sclera. Exp Eye Res. 1977;25:577-82.
18. Lee SJ, Kim ES, Geroski DH, McCarey B, Edelhauser HE. Pharmacokinetics of intraocular drug delivery of oregon green 488-labeled triamcinolone by subtenon injection using ocular fluorophotometry in rabbit eyes. Invest Ophthalmol Vis Sci. 2008;49(1):4506-14.
19. Tseng A, Foisy M. The role of ganciclovir for the management of cytomegalovirus retinitis in HIV patients: pharmacological review and update on new developments. Can J Infect Dis. 1996;7(3):183-94.
20. Morlet N, Young S, Naidoo D, Graham G, Coroneo MT. High dose intravitreal ganciclovir injection provides a prolonged therapeutic intraocular concentration. Br J Ophthalmol. 1996;80:214-6.
21. Mannermaa E, Vellonen K-S, Urtti A. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev. 2006;58(11):1136-63.